Literature DB >> 6296290

Identification of the envelope surface glycoproteins of equine herpesvirus type 1.

L W Turtinen, G P Allen.   

Abstract

The structural polypeptides of purified enveloped virions of the Army 183 strain of equine herpesvirus type 1 (EHV-1) were examined by different analytical techniques to identify the envelope glycoproteins. Glycoproteins were identified by electrophoretic analysis in polyacrylamide slab gels of virus labelled in vivo with [3H]glucosamine or labelled enzymically in vitro with either UDP-[14C]galactose or sodium [3H]borohydride. Fluorograms revealed eleven glycoproteins (mol. wt. 260000, 150000, 138000, 90000, 87000, 65000, 62000, 60000, 50000, 46000, and 24000). These glycoproteins probably correspond to virion protein (VP) 1-2, 9b, 10, 13, 14, 16, 17, 18, 21, 22a and 25 respectively, as designated in two other EHV-1 strains. In addition, a poorly resolved glucosamine-rich region (mol. wt. 250000 to 200000) corresponded to VP 3 to 8. The two isotopic surface labelling methods revealed that all the virus glycoproteins were exposed on the envelope surface.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296290     DOI: 10.1099/0022-1317-63-2-481

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Antigenic and protein sequence homology between VP13/14, a herpes simplex virus type 1 tegument protein, and gp10, a glycoprotein of equine herpesvirus 1 and 4.

Authors:  G R Whittaker; M P Riggio; I W Halliburton; R A Killington; G P Allen; D M Meredith
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

2.  Characterization of an antigenic site on glycoprotein 13 (gC) of equid herpesvirus type-1.

Authors:  R Sinclair; B J Moult; J A Mumford
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  The highly O-glycosylated glycoprotein gp2 of equine herpesvirus 1 is encoded by gene 71.

Authors:  J E Wellington; G P Allen; A A Gooley; D N Love; N H Packer; J X Yan; J M Whalley
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Identification and comparative sequence analysis of a gene in equine herpesvirus 1 with homology to the herpes simplex virus glycoprotein D gene.

Authors:  M Whalley; G Robertson; C Bell; D Love; M Elphinstone; L Wiley; D Craven
Journal:  Virus Genes       Date:  1991-10       Impact factor: 2.332

5.  Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1.

Authors:  D Tewari; J S Gibson; J D Slater; T O'Neill; D Hannant; G P Allen; H J Field
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Use of lambda gt11 and monoclonal antibodies to map the genes for the six major glycoproteins of equine herpesvirus 1.

Authors:  G P Allen; M R Yeargan
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Monoclonal antibodies with neutralizing activity to equine herpesvirus 1.

Authors:  M Shimizu; K Satou; N Nishioka
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.

Authors:  P X Guo; S Goebel; S Davis; M E Perkus; B Languet; P Desmettre; G Allen; E Paoletti
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Detection of antibodies against equine herpesvirus types 1 and 4 by using recombinant protein derived from an immunodominant region of glycoprotein B.

Authors:  R Sinclair; M M Binns; E D Chirnside; J A Mumford
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

10.  The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.

Authors:  Jens von Einem; Janet Wellington; J Millar Whalley; Kerstin Osterrieder; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.